Director Omar Ishrak filed a Form 4 with the SEC on November 7, 2026, reporting the acquisition of 152.0351 shares of Amgen Inc. common stock on November 6, 2026, through a vested Restricted Stock Unit grant at no cost.
Key Highlights
- Reporting person: Omar Ishrak, Director at Amgen Inc. (NASDAQ:AMGN)
- Transaction date: November 6, 2026, with the form signed and filed on November 7, 2026
- Shares acquired: 152.0351 shares of common stock via transaction code "A" (acquisition) at a price of $0
- Post-transaction holdings: 7,681.9397 shares of common stock beneficially owned directly following the reported transaction
- RSU grant details: Units granted under the Amgen Inc. 2009 Director Equity Incentive Program and vested immediately upon grant
- Dividend Equivalents: The reported shares include 504 Dividend Equivalents credited to the reporting person's unvested RSUs under a qualifying dividend reinvestment plan
Ishrak RSU Award and Dividend Equivalents Under Amgen's 2009 Equity Plan
According to the filing, Omar Ishrak, a director at Amgen Inc., acquired 152.0351 shares of the company's common stock on November 6, 2026, at a price of $0. The acquisition was coded "A" in Table I of the Form 4, indicating shares acquired rather than disposed of. Following the transaction, the filing reports Ishrak directly beneficially owned 7,681.9397 shares of Amgen common stock.
The filing discloses that the RSUs were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, and "vested immediately." The filing further notes that "Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis" and that "Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule."
The filing also explains that the reported shares include 504 Dividend Equivalents granted under the same equity plan. According to the filing, these Dividend Equivalents "are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount." No derivative securities transactions were reported in Table II of the form.
What Was Disclosed
Amgen director Omar Ishrak reported acquiring 152.0351 shares of common stock on November 6, 2026, at no cost through an immediately vested RSU grant under the company's 2009 Director Equity Incentive Program, bringing his direct beneficial ownership to 7,681.9397 shares.




Please wait processing your request...